ArticleBMC public health2025
Analysis of global burden of inflammatory bowel disease among adolescents and young adults from 1990 to 2021 and projections to 2040.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
- Gut microbiota in the pathogenesis and treatment of inflammatory bowel disease: a critical review of mechanisms and therapeutic advances.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic nonspecific intestinal disorder with peak onset ages in adolescents and young adults (AYA, aged 15-39) and a lifelong risk of recurrence. AYA constitute a significant and unique proportion of its disease burden, facing challenges in fertility preservation, psychosocial support, and economic impact. Accurate epidemiological insights are crucial for national disease control and prevention strategies, yet research on AYA IBD remains sparse. This study aims to assess the burden of AYA IBD from 1990 to 2021 by global, regional, national, socio-demographic index (SDI), sex and age group, and to predict the disease burden in 2040.
methodsUsing data from the Global Burden of Disease (GBD) study, we conducted a comprehensive analysis of disability-adjusted life years (DALYs), deaths, incidence, and prevalence of AYA IBD from 1990 to 2021, with subgroup analyses by region, country, SDI, sex and age group. We calculated the estimated annual percentage changes (EAPCs) of age-standardized rates (ASRs) to assess global trends in AYA IBD burden from 1990 to 2021. We also examined the correlations between EAPC and ASR as well as SDI across countries and projected the disease burden to 2040 with Bayesian age-period-cohort (BAPC) model.
resultsGlobally, AYA IBD DALYs increased from 246,873.18 in 1990 to 320,607.21 in 2021. By 2040, DALYs are projected to continue rising steadily. East Asia saw the most marked increases in age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR), at 3.28% and 2.60%, respectively. Australia experienced the steepest rises in age-standardized DALYs rate (ASDR) and mortality rate (ASMR), at 1.19% and 2.33%, respectively. High SDI countries still had the highest ASDR (21.90/100,000), ASIR (13.65/100,000), and ASPR (109.31/100,000) in 2021. Middle SDI countries exhibited the largest ASDR, ASIR and ASPR increases. In 2021, the EAPCs of ASDR and ASMR were negatively correlated with SDI. Females had higher ASDR, ASMR and ASPR. The highest disease burden was observed in the 35-39 age group.
conclusionAYA IBD represents a significant global public health burden, expected to persist through 2040. With the increasing aging population, policymakers should develop appropriate strategies to mitigate the burden of AYA IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.